5. Литература

Поставить закладку

1. Кокосадзе Н.В., Пробатова Н.А., Ковригина А.М., и соавт. Морфологическая диагностика MALT-лимфомы желудка. Вестник Московского онкологического общества.2009;10:2-4
2. Поддубная И.В., Османов Е.А., Москаленко О.А., и соавт. Клинические аспекты MALT-лимфом. Вестник Московского онкологического общества. 2009;10:5-6
3. KahlB,YangD.Marginalzonelymphomas:managementofnodal,splenic,andMALT NHL.HematologyAmSocHematolEducProgram.2008:359-64
4. Thieblemont C. Clinical presentation and management of marginal zone lymphomas. HematologyAmSocHematolEducProgram.2005:307-13
5. Swerdlow SH, Campo E, Harris NL, et al., eds. WHO classification of tumors of haematopoieticandlymphoidtissues(ed4th).Lyon:IARC;2008
6. Nathwani BN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma: A clinicalcomparisonofnodalandmucosa-associatedlymphoidtissuetypes.Non-Hodgkin's LymphomaClassificationProject.JClinOncol.1999;17(8):2486-92
7. Thieblemont C, Bastion Y, Berger F, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J ClinOncol.1997;15(4):1624-30
8. МалиховаО.А.,ПоддубныйБ.К.,ПоддубнаяИ.В.,исоавт.Неходжкинскиелимфомы желудка: современное состояние проблемы. Экспериментальная и клиническая гастроэнтерология.2010;9:33-37
9. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associatedlymphoidtissue.Blood.2003;101(7):2489-95
10. YeH,LiuH,RadererM,etal.Highincidenceoft(11;18)(q21;q21)inHelicobacterpylori-negativegastricMALTlymphoma.Blood.2003;101(7):2547-50
11. RohatinerA,d'AmoreF,CoiffierB,etal.Reportonaworkshopconvenedtodiscussthe pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5(5):397-400
12. Stathis A, Chini C, Bertoni F, et al. Long-term outcome following Helicobacter pylori eradicationinaretrospectivestudyof105patientswithlocalizedgastricmarginalzoneB-celllymphomaofMALTtype.AnnOncol.2009;20(6):1086-93
13. AndrianiA,MiedicoA,TedeschiL,etal.Managementandlong-termfollow-upofearly stage H. pylori-associated gastric MALT-lymphoma in clinical practice: an Italian, multicentrestudy.DigLiverDis.2009;41(7):467-73
14. NakamuraS,MatsumotoT,SuekaneH,etal.Long-termclinicaloutcomeofHelicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a referencetosecond-linetreatment.Cancer.2005;104(3):532-40
15. VrielingC,deJongD,BootH,etal.Long-termresultsofstomach-conservingtherapyin gastricMALTlymphoma.RadiotherOncol.2008;87(3):405-11
16. ESMO Guidelines Working Group. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 (Suppl 5):v175-6.
17. Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116(16):3815-24.
18. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005;23(9):1979-83
19. Arcaini L, Burcheri S, Rossi A, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist. 2006;11(3):285-91
20. Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia. 2004;18(10):1711-6
21. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol. 2005;23(3):468-73
22. Arcaini L, Vallisa D, Merli M, et al. Hematological response to antiviral treatment in 94 patients with indolent B-cell lymphomas associated with hepatitis C virus infection: a study of the Fondazione Italiana Linfomi (FIL). Ann Oncol 2011;22 (Supp 4): Abstract 138
23. Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006;107(1):125-35
24. Cervetti G, Galimberti S, Sordi E, et al. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. 2010;21(4):851-4.
25. Milosevic R, Todorovic M, Balint B, et al. Splenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphoma. World J Gastroenterol. 2009;15(32):4009-4015

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница